Abstract
BackgroundImmunotherapy is currently part of the standard of care for patients with advanced-stage non-small cell lung cancer (NSCLC). However, many patients do not respond to this treatment, therefore combination strategies...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have